Industry Outlook

The treatment-resistant depression treatment market is exhibiting good growth at a compounded annual growth rate (CAGR) of 3.6% during the forecast period from 2023 to 2030. Depression is the most common mental disorder affecting approximately 300 million people worldwide. The prevalence rate is high in women in comparison to men. In the last 2 decades there has been significant rise in the number of ailing patients showing resistance to first line therapy drugs for treating depression. Recently USFDA gave approval to Esketamine nasal sprays for treating TRD. Currently AXS-05 drug developed by Axsome Therapeutics, Inc., is under phase III clinical trial investigation for its application in treating TRD.

Recent USFDA approval of Spravato (esketamine nasal spray) will register impressive growth during the forecast period

In one third of the patients suffering with depression treatment resistant in encountered when patients fail to respond to first line therapy drugs. The underlying factor responsible for this resistance is not known, accurate diagnosis and identification of possible cormorbid condition determines treatment-resistant depression (TRD) in ailing patients worldwide. The treatment regimen followed is prescribing drugs such as SSRI’s, MAOI’s, tricyclic antidepressant and serotonin 1A receptor agonist for treating TRD. Increasing the dose of prescribed medicine to maximum toleration level, combination of antidepressants or switching to different class of antidepressant is the best possible and conventional method adopted in its treatment globally. Recently USFDA has approved Esketamine nasal spray (Spravato) developed by Janssen Pharmaceutical, Inc., as the novel prescription drug for treating TRD in conjunction with an oral antidepressant. Researchers anticipate its faster adoption rate owing to its excellent pharmacokinetic and pharmacodynamic profile observed during clinical trial investigation.

Growing incidence of depression and anxiety to drive the market growth in North America region

North America with a share of 34.2% is dominating the regional segment for treatment-resistant depression treatment market. According to the latest statistics provided by Center for Disease Control and Prevention (CDC) the incidence rate of suicidal deaths is 14.5 per 100,000 people in the United States. Affordable reimbursement scenario for the drugs employed in treating mental disorders further propels the market growth in the region. In the second place is Europe representing a market share of 30.5% owing to the domicile of key players such as Novartis AG, Janssen Pharmaceuticals, Inc., Pfizer, Inc., Mylan Pharmaceuticals, Inc. etc. Asia Pacific is currently holding 17.3% market share on account of rising prevalence of mental disorders, effective implementation of treatment regiment to treat depression and suicidal tendency across all age groups.

Pharmaceutical companies manufacturing drugs for the treatment regimen of treatment-resistant depression are Bristol Myers Squibb Company, Eli Lilly & Company, Janssen Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Valeant Pharmaceuticals International, Validus Pharmaceuticals LLC and Wyeth.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Treatment-Resistant Depression (TRD) Treatment market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Treatment-Resistant Depression (TRD) Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Treatment-Resistant Depression (TRD) Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Treatment-Resistant Depression (TRD) Treatment market?
• Which is the largest regional market for Treatment-Resistant Depression (TRD) Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Treatment-Resistant Depression (TRD) Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Treatment-Resistant Depression (TRD) Treatment market worldwide?